Young, Kim Do

Товч нэр

Young, Kim Do

Бүтэн нэр

Young Kim Do

Латин нэр

Young Kim Do

Албан тушаал

Судлаач

Харьяалал

Анагаахын Шинжлэх Ухааны Үндэсний Их Сургууль

Now showing 1 - 10 of 21

Some of the metrics are blocked by your
consent settings
Viral Hepatitis and Liver Diseases in Mongolia
(Jaypee Brothers Medical Publishing, 2017-06-01)
Baatarkhuu, Oidov
;
Uugantsetseg, G
;
Munkh-Orshikh, D
;
Naranzul, N
;
Badamjav, S
Some of the metrics are blocked by your
consent settings
Lower Incidence of Hepatocellular Carcinoma and Cirrhosis in Hepatitis C Patients with Sustained Virological Response by Pegylated Interferon and Ribavirin
(Springer Science and Business Media LLC, 2015-02)
Moon, Chansoo
;
Jung, Kyu Sik
;
Kim, Do Young
;
Baatarkhuu, Oidov
;
Park, Jun Yong
Scopus© Citations 38
Some of the metrics are blocked by your
consent settings
Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals
(Springer Science and Business Media LLC, 2019-02)
Lee, Hye Won
;
Kim, Seung Up
;
Baatarkhuu, Oidov
;
Park, Jun Yong
;
Kim, Do Young
Routine nucleos(t)ide analogs (NUCs) have not yet been recommended for patients with immune-tolerant (IT) phase in chronic hepatitis B virus (HBV) infection. We aimed to evaluate prognosis of patients in untreated IT-phase (UIT group), compared to those in immune-active phase who achieved virological response by NUCs according to guidelines (VR group). Between 2006 and 2012, patients in UIT or VR groups were included. Cumulative risks of HCC and liver-related events (LREs) development were assessed. Furthermore, propensity-score was calculated based upon age, gender, diabetes and liver stiffness. UIT group (n = 126) showed younger age, lower proportion of male gender and lower LS than VR group (n = 641). UIT group had similar 10-year cumulative risks of HCC (2.7% vs. 2.9%, p = 0.704) and LRE (4.6% vs. 6.1%, p = 0.903) development, compared to VR group. When we re-defined UIT group by the lower ALT cut-offs, 10-year cumulative risks of HCC and LRE development were 2.9% and 4.8%, respectively. Using propensity-score matching and inverse probability treatment weighting analysis, similar results were reproduced. UIT group consistently had similar prognosis compared to VR group. Therefore, further large-scale prospective studies in order to verify rationales of routine NUCs in UIT group are still required.
Scopus© Citations 31
Some of the metrics are blocked by your
consent settings
Conditional Survival Estimates Improve Over Time for Patients with Hepatocellular Carcinoma: An Analysis for Nationwide Korea Cancer Registry Database
(Korean Cancer Association, 2019-10)
Lee, Jae Seung
;
Cho, In Rae
;
Lee, Hye Won
;
Jeon, Mi Young
;
Lim, Tae Seop
PURPOSE: Conditional survival estimates (CSE) can provide additional useful prognostic information on the period of survival after diagnosis, which helps in counseling patients with cancer on their individual prognoses. This study aimed to analyze conditional survival (CS) for hepatocellular carcinoma (HCC) using a Korean national registry. MATERIALS AND METHODS: Patients with HCC, registered in the Korean cancer registry database, were retrospectively reviewed. Overall survival (OS) was calculated using the Kaplan-Meier method. The 1-year CS at X year or month after diagnosis were calculated as CS1=OS(X+1)/OS(X). CS calculations were performed in each Barcelona Clinic Liver Cancer stage, after which patients at stage 0, A, and B underwent subgroup analysis using initial treatment methods. RESULTS: A total of 4,063 patients diagnosed with HCC from January 2008 to December 2010, and 2,721 who were diagnosed from January 2011 to December 2012, were separately reviewed. In 2008-2010, the 1-year CS of 1, 2, 3, 4, and 5-year survivors was 82.9%, 85.1%, 88.3%, 88.0%, and 88.6%, respectively. Patients demonstrated an increase in CSE over time in subgroup analysis, especially in the advanced stages. In 2011-2012, the 1-year CS of 6, 12, 18, 24, 30, and 36 months was 81.5%, 83.8%, 85.3%, 85.5%, 86.5%, and 88.8%, respectively. The subgroup analysis showed the same tendency towards increased CSE in the advanced stages. CONCLUSION: Overall, the CS improved with each additional year after diagnosis in both groups. CSE may therefore provide a more accurate prognosis and hopeful message to patients who are surviving with or after treatment.
Scopus© Citations 10
Some of the metrics are blocked by your
consent settings
Variability in liver stiffness values from different intercostal spaces
(Wiley, 2009-05)
Kim, Seung Up
;
Kim, Ja Kyung
;
Park, Jun Yong
;
Ahn, Sang Hoon
;
Lee, Jung Min
Scopus© Citations 22
Some of the metrics are blocked by your
consent settings
Author Correction: Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals
(2019-11)
Lee, Hye Won
;
Kim, Seung Up
;
Baatarkhuu, Oidov
;
Park, Jun Yong
;
Kim, Do Young
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Scopus© Citations 2
Some of the metrics are blocked by your
consent settings
Antiviral efficacy of lamivudine versus entecavir in patients with hepatitis B virus‐related advanced hepatocellular carcinoma
(Wiley, 2012-09)
Shin, Hye Sun
;
Kim, Seung Up
;
Park, Jun Yong
;
Kim, Do Young
;
Han, Kwang‐Hyub
Scopus© Citations 16
Some of the metrics are blocked by your
consent settings
Association Between Level of Fibrosis, Rather Than Antiviral Regimen, and Outcomes of Patients With Chronic Hepatitis B
(Elsevier BV, 2016-11)
Kim, Hye Soo
;
Kim, Beom Kyung
;
Kim, Seung Up
;
Park, Jun Yong
;
Kim, Do Young
BACKGROUND & AIMS: We performed a propensity-score matched analysis to investigate whether entecavir, compared with lamivudine, can reduce risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B after adjusting for level of fibrosis. METHODS: We performed a retrospective study of 1079 patients with chronic hepatitis B who received first-line therapy with lamivudine (n = 435) or entecavir (n = 644) from 2006 through 2013. Only patients with available liver stiffness value measured by transient elastography were recruited. Liver cirrhosis was diagnosed by ultrasonography. To adjust for the imbalance of patients treated with lamivudine versus entecavir, we performed propensity-score matching (PSM), at a ratio of 1:1, using 7 factors (age, sex, hepatitis B e antigen, alanine aminotransferase, serum albumin, platelet count, and liver stiffness; PSM1) or 8 factors (variables of PSM1 plus ultrasonography measurements of cirrhosis; PSM2). Patients with virologic breakthrough or resistance mutations received rescue therapy. RESULTS: Over the 7-year period, 91 patients developed HCC and 104 had liver-related events in the entire cohort. In multivariate analyses, level of fibrosis, but not antiviral regimen, was independently associated with risk of HCC (P < .05). The PSM1 group included 342 pairs of patients and the PSM2 group included 338 pairs. Similar proportions of patients given lamivudine versus entecavir developed HCC in each model (10.5% given lamivudine vs 9.9% given entecavir in PSM1 and 11.9% vs 12.6% in PSM2; all P > .05). When PSM was applied to patients with liver stiffness value ≤13 kPa or >13 kPa, patients given lamivudine versus entecavir still had similar cumulative rates of HCC development (all P > .05). CONCLUSIONS: In a PSM analysis, we associated level of fibrosis, rather than antiviral regimen, with risk of HCC, when patients received appropriate rescue therapy in case of virologic breakthrough or resistance mutations.
Scopus© Citations 38
Some of the metrics are blocked by your
consent settings
Prevalence and genotype distribution of hepatitis C virus among apparently healthy individuals in Mongolia: a population‐based nationwide study
(Wiley, 2008-11)
Baatarkhuu, Oidov
;
Kim, Do Young
;
Ahn, Sang Hoon
;
Nymadawa, Pagvajav
;
Dahgwahdorj, Yagaanbuyant
Scopus© Citations 31
Some of the metrics are blocked by your
consent settings
Clinical features and prognosis of hepatocellular carcinoma in Mongolia: a multicentre study
(Springer Science and Business Media LLC, 2012-10)
Baatarkhuu, Oidov
;
Kim, Do Young
;
Nymadawa, Pagbajabyn
;
Kim, Seung Up
;
Han, Kwang-Hyub
Scopus© Citations 11

Young, Kim Do

Filters

Settings

Sort By

Results per page